Stock comparison
Genmab A/S
Sanofi
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
SNY
Sanofi
Market cap
$106.67B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SNY | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 61C | GMAB |
| Benjamin Graham | 64C | 40D | GMAB |
| Philip Fisher | 48D | 53C | SNY |
| Peter Lynch | 25F | 39D | SNY |
| Joel Greenblatt | 76B | 39D | GMAB |
| Charlie Munger | 68C | 48D | GMAB |
| Terry Smith | 71C | 49D | GMAB |
Side-by-side metrics
| Metric | GMAB | SNY |
|---|---|---|
| Market cap | $16.5B | $106.67B |
| P/E (TTM) | 6.2x | 8.6x |
| EV/EBIT | 12.0x | 10.8x |
| ROIC (TTM) | 43.78% | 11.66% |
| Gross margin | 93.88% | 71.62% |
| Net margin | 18.23% | 17.59% |
| Revenue CAGR 5y | -18.45% | 4.5% |
| EPS CAGR 5y | -23.48% | 6.47% |
| Debt / Equity | 0.1x | 0.3x |
| Dividend yield | 0.0% | 5.57% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 11.66%+73%
- Debt / Equity0.1xvs 0.3x+73%
- P/E (TTM)6.2xvs 8.6x+28%
- Gross margin93.88%vs 71.62%+24%
SNY leads on
- EPS CAGR 5y6.47%vs -23.48%+128%
- Revenue CAGR 5y4.5%vs -18.45%+124%
- Dividend yield5.57%vs 0.0%+100%
- Market cap$106.67Bvs $16.5B+85%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.